FindTrial
Sign In

Use of Serum Periostin Level to Predict Exacerbation in Moderate to Severe Asthma Patients

Use of Serum Periostin Level to Predict Exacerbation in Moderate to Severe Asthma Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20200525001
Enrollment
Unknown
Registered
2020-05-25
Start date
2018-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate to severe asthma Asthma periostin

Interventions

Comparison of serum periostin level
Screening
Asthma

Sponsors

Department of medicine
Lead Sponsor
Phramongkutklao college of medicine
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: All patients were diagnosed moderate to severe asthma according to Global Strategy for Asthma Management and Prevention (GINA) updated 2018. Ages over 18 years

Exclusion criteria

Exclusion criteria: Chronic obstructive pulmonary disease (COPD), asthma – COPD overlap, Idiopathic pulmonary fibrosis (IPF),pregnancy women and end-stage of chronic disease

Design outcomes

Primary

MeasureTime frame
serum periostin level and number of asthma exacerbation 24 weeks serum periostin level by ELISA—

Secondary

MeasureTime frame
symptom control 24 weeks Asthma Control Questionnaire (ACQ) and Asthma Control Test (ACT)—

Countries

Thailand

Contacts

Public ContactPrapun Kittivoravitkul

Phramongkutklao hospital

prapunn@hotmail.com0948951526

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026